Back to top

blockchain: Archive

Zacks Equity Research

Silk Road Medical (SILK) Stock Jumps 6.7%: Will It Continue to Soar?

Silk Road Medical (SILK) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

SILKNegative Net Change

Zacks Equity Research

Here is Why Growth Investors Should Buy Watsco (WSO) Now

Watsco (WSO) is well positioned to outperform the market, as it exhibits above-average growth in financials.

WSONegative Net Change

Zacks Equity Research

3 Reasons Growth Investors Will Love Daqo (DQ)

Daqo (DQ) is well positioned to outperform the market, as it exhibits above-average growth in financials.

DQPositive Net Change

Zacks Equity Research

3 Reasons Growth Investors Will Love United (UAL)

United (UAL) is well positioned to outperform the market, as it exhibits above-average growth in financials.

UALNegative Net Change

Zacks Equity Research

All You Need to Know About United (UAL) Rating Upgrade to Buy

United (UAL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

UALNegative Net Change

Zacks Equity Research

Professional Holding (PFHD) Upgraded to Buy: Here's What You Should Know

Professional Holding (PFHD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Equity Research

What Makes Greif (GEF) a New Buy Stock

Greif (GEF) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

GEFNegative Net Change

Zacks Equity Research

All You Need to Know About Codiak BioSciences, Inc. (CDAK) Rating Upgrade to Strong Buy

Codiak BioSciences, Inc. (CDAK) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Equity Research

All You Need to Know About First Interstate BancSystem (FIBK) Rating Upgrade to Strong Buy

First Interstate BancSystem (FIBK) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

FIBKNegative Net Change

Zacks Equity Research

Why Is AutoZone (AZO) Up 8.2% Since Last Earnings Report?

AutoZone (AZO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

AZOPositive Net Change

Zacks Equity Research

Vertiv Holdings Co. (VRT) Surges 5.7%: Is This an Indication of Further Gains?

Vertiv Holdings Co. (VRT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

VRTNegative Net Change GDYNNegative Net Change

Zacks Equity Research

Strength Seen in Antero Resources (AR): Can Its 5.5% Jump Turn into More Strength?

Antero Resources (AR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

ARNegative Net Change APAPositive Net Change

Zacks Equity Research

Does Albertsons Companies, Inc. (ACI) Have the Potential to Rally 29% as Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 28.5% in Albertsons Companies, Inc. (ACI). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

ACIPositive Net Change

Zacks Equity Research

Wall Street Analysts Believe MRC (MRC) Could Rally 64%: Here's is How to Trade

The mean of analysts' price targets for MRC (MRC) points to a 64.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

MRCNegative Net Change

Zacks Equity Research

Does Nabors (NBR) Have the Potential to Rally 31% as Wall Street Analysts Expect?

The mean of analysts' price targets for Nabors (NBR) points to a 30.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

NBRNegative Net Change

Zacks Equity Research

Wall Street Analysts Think SpringWorks Therapeutics (SWTX) Could Surge 212%: Read This Before Placing a Bet

The mean of analysts' price targets for SpringWorks Therapeutics (SWTX) points to a 211.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Zacks Equity Research

Does Fortinet (FTNT) Have the Potential to Rally 37% as Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 37.4% in Fortinet (FTNT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

FTNTNegative Net Change

Zacks Equity Research

Does Upstart Holdings, Inc. (UPST) Have the Potential to Rally 85% as Wall Street Analysts Expect?

The consensus price target hints at an 84.7% upside potential for Upstart Holdings, Inc. (UPST). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

UPSTPositive Net Change

Zacks Equity Research

Does Navigator Holdings (NVGS) Have the Potential to Rally 33% as Wall Street Analysts Expect?

The mean of analysts' price targets for Navigator Holdings (NVGS) points to a 33.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

NVGSNegative Net Change

Zacks Equity Research

Does BlueLinx (BXC) Have the Potential to Rally 60% as Wall Street Analysts Expect?

The mean of analysts' price targets for BlueLinx (BXC) points to a 60% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

BXCPositive Net Change

Zacks Equity Research

Wall Street Analysts Believe Driven Brands Holdings Inc. (DRVN) Could Rally 32%: Here's is How to Trade

The average of price targets set by Wall Street analysts indicates a potential upside of 32.4% in Driven Brands Holdings Inc. (DRVN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

DRVNPositive Net Change

Zacks Equity Research

Does NortonLifeLock (NLOK) Have the Potential to Rally 26% as Wall Street Analysts Expect?

The consensus price target hints at a 25.8% upside potential for NortonLifeLock (NLOK). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks Equity Research

Allison Transmission (ALSN) is a Top-Ranked Momentum Stock: Should You Buy?

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

ALSNNegative Net Change

Zacks Equity Research

Kymera Therapeutics, Inc. (KYMR) Moves 9.6% Higher: Will This Strength Last?

Kymera Therapeutics, Inc. (KYMR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

KYMRNegative Net Change DBVTNegative Net Change

Zacks Equity Research

Cross Country Healthcare, Inc. (CCRN) Hit a 52 Week High, Can the Run Continue?

Cross Country (CCRN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

CCRNNegative Net Change